Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimoxamine SCHEMBL896149 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL894999 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL29633087 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL29543489 | 1.00 | TAAR1 (0.54) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL30855253 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL3142009 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL121888 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL30855252 | 0.98 | TAAR1 (0.53) | TAAR1HTR2A | |
| Dimoxamine SCHEMBL3147518 | 0.97 | TAAR1 (0.51) | TAAR1HTR2A | |
| SCHEMBL11737197 | 0.91 | TAAR1 (0.45) | TAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214011-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | ENZYMICALS AG (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4273254-A1 | ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES | Enzymicals AG (DE) | 2023-11-08 | — | — | EP | claimed |
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | claimed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | claimed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | claimed |
| EP-2744908-A1 | ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE CHIRAL AMINES | Embio Limited (IN) | 2014-06-25 | — | — | EP | claimed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20140099682-A1 | Enzymatic Synthesis of Optically Active Chiral Amines | EMBIO LIMITED (IN) | 2014-04-10 | — | — | US | claimed |
| WO-2013024453-A1 | ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE CHIRAL AMINES | EMBIO LIMITED (IN) | 2013-02-21 | — | — | WO | claimed |
| EP-2462115-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | Infinity Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | claimed |
| WO-2011017551-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| US-4034113-A | Treatment of senile geriatric patients to restore performance | SHULGIN ALEXANDER T | 1977-07-05 | — | — | US | claimed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | CODEXIS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| EP-0404146-A2 | Enantiomeric enrichment and stereoselective synthesis of chiral amines | CELGENE CORPORATION (US) | 1990-12-27 | — | — | EP | disclosed |
| US-4950606-A | CONTACTING IN AN AQUEOUS MEDIUM IN THE PRESENCE OF AN AMINO ACCEPTOR WITH AN OMEGA-AMINO ACID TRANSAMINASE TO CONVERT ONE OF AMINES TO KETONE | CELGENE CORPORATION (US) | 1990-08-21 | — | — | US | disclosed |
| US-4034113-A | Treatment of senile geriatric patients to restore performance | SHULGIN ALEXANDER T | 1977-07-05 | — | — | US | disclosed |
| US-4008243-A | Antiviral thiazolinyl or thiazinyl benzimidazole esters | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | TAAR1 46/4885HTR2A 6/4885 |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | TAAR1 2537/4885HTR2A 4028/4885 |
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | XDH, AGXT, PEPD | TAAR1 684/4885HTR2A 4156/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | TAAR1 77/4885HTR2A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.